Suspended

Semaglutide for Ovulation, Menstrual Regularity and Androgen Levels in Polycystic Ovarian Syndrome

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This phase 1 study aims to evaluate your compliance and persistence with Semaglutide therapy, by observing the number of appropriate weekly doses and the number of days on therapy, as a treatment for Polycystic Ovarian Syndrome.

What is being tested

Semaglutide

Drug
Who is being recruted

Urogenital Diseases+10

+ Genital Diseases

+ Adnexal Diseases

From 18 to 45 Years
+11 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1
Interventional
Study Start: February 2026
See protocol details

Summary

Principal SponsorMethodist Health System
Last updated: March 24, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2026

Actual date on which the first participant was enrolled.

This clinical trial investigates the effects of a medication called semaglutide on women with Polycystic Ovarian Syndrome (PCOS). PCOS is a common condition that affects hormone levels, leading to symptoms like irregular menstrual cycles and excessive hair growth. The study aims to see if semaglutide can help improve these symptoms by regulating ovulation and menstrual cycles, as well as reducing levels of male hormones like testosterone. Additionally, it examines whether semaglutide can help manage weight and blood sugar levels, which are often concerns for those with PCOS. Participants in the study will receive semaglutide, which is usually administered as an injection. The researchers will monitor changes in menstrual regularity and hormone levels to assess the drug's impact. They will also evaluate any weight loss and improvements in blood sugar levels, measured by Glycated Hemoglobin (HbA1c). By tracking these outcomes, the study aims to discover how effective semaglutide might be as a treatment option for alleviating the symptoms of PCOS.

Official TitleSemaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
NCT06222437
Principal SponsorMethodist Health System
Last updated: March 24, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 45 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesAdnexal DiseasesCystsEndocrine System DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGonadal DisordersNeoplasmsOvarian CystsOvarian DiseasesPolycystic Ovary SyndromeFemale Urogenital Diseases

Criteria

4 inclusion criteria required to participate
Age 18-45
Body mass index(BMI) > 30
Diagnosis of PCOS
Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone
7 exclusion criteria prevent from participating
Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
Letrozole, clomiphene citrate, FSH therapy
Androgen receptor blockers
5α reductase inhibitors
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
PCOS women in the age 18 to 45 years

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
SuspendedNo study centers
Semaglutide for Ovulation, Menstrual Regularity and Androgen Levels in Polycystic Ovarian Syndrome | PatLynk